For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Sales | - | 820,188 | 1,120,121 | 1,888,838.5* |
| Cost of sales | - | 635,994 | 716,962 | 922,372* |
| Gross profit | - | 184,194 | 403,159 | 966,466.5* |
| Research and development | 1,022,630 | 630,636 | 581,612 | 540,380* |
| General and administrative | 1,742,016 | 1,621,095 | 1,532,015 | 5,906,910.5* |
| Amortization and depreciation | 51,707 | 53,201 | 53,202 | 49,102* |
| Foreign exchange loss | -23,168 | 18,136 | -56,994 | -7,117.75* |
| Total operating expenses | 2,839,521 | 2,286,796 | 2,223,823 | 6,503,510.25* |
| Interest and other income | 47,770 | 74,379 | 93,765 | -15,400* |
| Finance expense | - | - | - | 92,887.25* |
| Net loss from continuing operations before taxes | -2,791,751 | -2,028,223 | -1,726,899 | -5,645,331 |
| Net loss from continuing operations | -2,791,751 | - | - | - |
| Income (loss) from discontinued operations | -174,585 | - | - | - |
| Loss from discontinued operations | -174,585 | - | - | - |
| Net loss | -2,966,336 | -2,028,223 | -1,726,899 | -5,645,331 |
| Basic EPS | -0.73 | -0.51 | -0.44 | -5.784 |
| Diluted EPS | -0.73 | -0.51 | -0.44 | -5.784 |
| Basic Average Shares | 4,048,209 | 3,954,549 | 3,954,549 | 975,985* |
| Diluted Average Shares | 4,048,209 | 3,954,549 | 3,954,549 | 975,985* |
InMed Pharmaceuticals Inc. (INM)
InMed Pharmaceuticals Inc. (INM)